company background image
OVN

Oventus Medical ASX:OVN Stock Report

Last Price

AU$0.02

Market Cap

AU$4.8m

7D

0%

1Y

-81.0%

Updated

09 Aug, 2022

Data

Company Financials +
OVN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

OVN Stock Overview

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States.

Oventus Medical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oventus Medical
Historical stock prices
Current Share PriceAU$0.02
52 Week HighAU$0.15
52 Week LowAU$0.017
Beta0.89
1 Month Change0%
3 Month Change-9.09%
1 Year Change-80.95%
3 Year Change-95.46%
5 Year Change-93.55%
Change since IPO-97.14%

Recent News & Updates

Shareholder Returns

OVNAU Medical EquipmentAU Market
7D0%3.9%0.7%
1Y-81.0%-18.0%-8.0%

Return vs Industry: OVN underperformed the Australian Medical Equipment industry which returned -18% over the past year.

Return vs Market: OVN underperformed the Australian Market which returned -8% over the past year.

Price Volatility

Is OVN's price volatile compared to industry and market?
OVN volatility
OVN Average Weekly Movementn/a
Medical Equipment Industry Average Movement11.5%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: Insufficient data to determine OVN's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine OVN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aJohn Coxhttps://o2vent.com

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. The company offers O2Vent Optima, a 3D-printed nylon oral appliance for OSA patients; and ExVent, a valve accessory that fits into the open airway of the O2Vent Optima device. The company was incorporated in 2015 and is headquartered in Indooroopilly, Australia.

Oventus Medical Fundamentals Summary

How do Oventus Medical's earnings and revenue compare to its market cap?
OVN fundamental statistics
Market CapAU$4.83m
Earnings (TTM)-AU$10.29m
Revenue (TTM)AU$1.09m

4.4x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OVN income statement (TTM)
RevenueAU$1.09m
Cost of RevenueAU$654.09k
Gross ProfitAU$439.45k
Other ExpensesAU$10.73m
Earnings-AU$10.29m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.043
Gross Margin40.18%
Net Profit Margin-941.33%
Debt/Equity Ratio0%

How did OVN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is OVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OVN?

Other financial metrics that can be useful for relative valuation.

OVN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA-0.08x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OVN's PS Ratio compare to its peers?

OVN PS Ratio vs Peers
The above table shows the PS ratio for OVN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.3x
DVL dorsaVi
2.2xn/aAU$5.2m
UCM Uscom
3.5xn/aAU$11.9m
AMT Allegra Orthopaedics
3.3xn/aAU$17.8m
CBL Control Bionics
4.4x40.0%AU$18.5m
OVN Oventus Medical
4.4x90.2%AU$4.8m

Price-To-Sales vs Peers: OVN is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (3.3x).


Price to Earnings Ratio vs Industry

How does OVN's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

Price-To-Sales vs Industry: OVN is good value based on its Price-To-Sales Ratio (4.4x) compared to the Australian Medical Equipment industry average (6.8x)


Price to Sales Ratio vs Fair Ratio

What is OVN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OVN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ratio33.7x

Price-To-Sales vs Fair Ratio: OVN is good value based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (33.7x).


Share Price vs Fair Value

What is the Fair Price of OVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OVN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OVN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Oventus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OVN's revenue (90.2% per year) is forecast to grow faster than the Australian market (5.6% per year).

High Growth Revenue: OVN's revenue (90.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OVN is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Oventus Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-14.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OVN is currently unprofitable.

Growing Profit Margin: OVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVN is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.

Accelerating Growth: Unable to compare OVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).


Return on Equity

High ROE: OVN has a negative Return on Equity (-128.86%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Oventus Medical's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OVN's short term assets (A$5.7M) exceed its short term liabilities (A$1.6M).

Long Term Liabilities: OVN's short term assets (A$5.7M) exceed its long term liabilities (A$296.8K).


Debt to Equity History and Analysis

Debt Level: OVN is debt free.

Reducing Debt: OVN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OVN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OVN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7% each year


Discover healthy companies

Dividend

What is Oventus Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OVN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

John Cox

1.17yrs

Tenure

AU$517,485

Compensation

Mr. John Cox has been President and Chief Operating Officer of Oventus Medical Limited since June 7, 2021 and serves as its Chief Executive Officer since February 1, 2022. He serves as President and Chief...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD362.23K) is about average for companies of similar size in the Australian market ($USD279.73K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


Leadership Team

Experienced Management: OVN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: OVN's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oventus Medical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Oventus Medical Limited
  • Ticker: OVN
  • Exchange: ASX
  • Founded: 2015
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: AU$4.835m
  • Shares outstanding: 241.73m
  • Website: https://o2vent.com

Location

  • Oventus Medical Limited
  • 1 Swann Road
  • Suite 1
  • Indooroopilly
  • Queensland
  • 4068
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/06/07 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.